Skip to menu Skip to content Skip to footer
Dr Jodi Saunus
Dr

Jodi Saunus

Email: 

Overview

Background

Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.

Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:

  • Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
  • Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
  • Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.

With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).

Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.

Availability

Dr Jodi Saunus is:
Available for supervision
Media expert

Qualifications

  • Doctor of Philosophy, The University of Queensland

Research interests

  • Biomarkers of triple-negative breast cancer progression and response to therapy

    Using published datasets, and tissue donated by Brisbane breast cancer patients, we're trying to identify new biomarkers of prognosis and treatment response in breast cancer.

  • Understanding how the triple-negative breast cancer transcriptome is rewired during tumour progression

    We apply mathematical approaches to analyse transcriptional networks in TNBC, illuminating how cell biology evolves during tumour development and post-treatment relapse.

  • Understanding the brain metastasis immune microenvironment

    In collaboration with immuno-oncology experts at the Peter MacCallum Cancer Centre in Melbourne, we are studying the expression of common tumour antigens to develop strategies for vaccination against cancer.

  • Therapeutic antibody uptake in brain metastases

    Brain metastases are broadly refractory to existing systemic therapies. We believe that abnormal vascular function and interstitial fluid dynamics in these tumours may contribute more than previously appreciated. We aim to engineer molecular-targeted carriers that improve the effectiveness and reduce the side-effects of radiotherapy and chemotherapy.

Works

Search Professor Jodi Saunus’s works on UQ eSpace

104 works between 2002 and 2025

101 - 104 of 104 works

2005

Conference Publication

Hur post-transcriptionally regulates BRCA1: involvement of elements in the BRCA1 3' untranslated region

Saunus, J. M., Wardrop, S. L., French, J. D., Beveridge, D. J., Hatchell, E. C., Gason, A. A., Simpson, K.J., Leedman, P. J. and Brown, M. A. (2005). Hur post-transcriptionally regulates BRCA1: involvement of elements in the BRCA1 3' untranslated region. Molecular Approaches to Controlling Cancer, New York, 3-5 June, 2005.

Hur post-transcriptionally regulates BRCA1: involvement of elements in the BRCA1 3' untranslated region

2005

Conference Publication

Transcriptional and post-transcriptional regulation of the breast cancer susceptibility gene 1 (BRCA1)

Wardrop, S. L., Saunus, J. M., French, J. D., Leedman, P. J. and Brown, M. A. (2005). Transcriptional and post-transcriptional regulation of the breast cancer susceptibility gene 1 (BRCA1). National Cancer Research Institute Conference, Birmingham, UK, 2-5 Oct, 2005.

Transcriptional and post-transcriptional regulation of the breast cancer susceptibility gene 1 (BRCA1)

2005

Conference Publication

Regulation of BRCA1 by Heregulin

French, J. D., Saunus, J. M., Wardrop, S. L. and Brown, M. A. (2005). Regulation of BRCA1 by Heregulin. Familial Cancer 2005: Research and Practice, Couran Cove, 30 Aug - 3 Sept, 2005.

Regulation of BRCA1 by Heregulin

2002

Conference Publication

Identification of cis and trans regulators in the BRCA1 3'untranslated region

Saunus, J. M., Wardrop, S. L. and Brown, M. A. (2002). Identification of cis and trans regulators in the BRCA1 3'untranslated region. ComBio 2002, Sydney, Australia, 29 September - 3 October, 2002. Kent Town, South Australia:

Identification of cis and trans regulators in the BRCA1 3'untranslated region

Funding

Current funding

  • 2023 - 2028
    ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
    ARC Industrial Transformation Research Hubs
    Open grant

Past funding

  • 2021 - 2023
    ACRF Facility for Targeted Radiometals in Cancer (AFTRiC)
    Australian Cancer Research Foundation
    Open grant
  • 2020
    Identification and validation of novel classes of clinically relevant CD8 tumour antigens for cancer vaccination: supporting translational pipeline feasibility
    PA Research Foundation
    Open grant
  • 2020 - 2021
    New immunotherapeutic options for triple negative and brain metastatic breast cancer: next generation cancer vaccines exploiting new classes of tumour antigens
    National Breast Cancer Foundation Investigator Initiated Research Scheme
    Open grant
  • 2019 - 2021
    Nanomedicine strategies for early detection and treatment of brain metastases
    NHMRC Project Grant
    Open grant
  • 2017 - 2021
    Exploiting the Remodeling of Ca2+ Signaling in Breast Cancer Cell Microenvironments to Control Metastasis and to Specifically Target Brain Metastases
    United States Congressionally Directed Medical Research Programs - Breast Cancer Research Program
    Open grant
  • 2015 - 2016
    Repurposing pertuzumab for adjuvant treatment of breast cancer patients with HER2-positive brain metastases
    ANZBCTG Discretionary Funding - Research Seed Funding
    Open grant
  • 2014 - 2015
    The Brisbane Breast Bank
    Royal Brisbane and Women's Hospital Foundation
    Open grant
  • 2013 - 2015
    Prospective study of breast cancer progression by content analysis of circulating exosomes in serially collected blood samples
    Royal Brisbane and Women's Hospital
    Open grant
  • 2010
    Applying Inducible Pluripotent Stem (iPS) Cell Technology to Mammary Biology Research.
    UQ Early Career Researcher
    Open grant
  • 2010
    Isolation of oral epithelial stem cells from normal and dysplastic oral mucosa
    Dental Research Grant Scheme
    Open grant
  • 2010 - 2011
    Molecular validation of autofluorescence and narrow band imaging of oral cancer resection margins
    Dental Research Grant Scheme
    Open grant
  • 2009
    Isolation of Epithelial Stem Cells from Normal and Dysplastic Oral Epithelium.
    Ian Potter Foundation
    Open grant

Supervision

Availability

Dr Jodi Saunus is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Development of new theranostic agents for metastatic breast cancer surveillance and treatment

    Most of the time, treatments for early breast cancer successfully prevent metastatic spread, but 10% of Australian patients still develop lethal recurrences within 5 years. Rather than waiting to see which patients develop symptoms of a possible relapse (e.g., headaches, respiratory symptoms), we are getting better at detecting metastasis early. Patients deemed to be at ‘high risk’ are offered regular PET or MRI scans, allowing earlier intervention and better quality-of-life. PET imaging of radioactive tracers is more specific than MRI, but the standard tracer used in oncology – [18F]fluorodeoxyglucose (FDG) – is not useful for imaging the brain. We are seeking a student to help us develop agents that seek out tumour cells more specifically than FDG and can also be engineered to function as therapeutics. The project is flexible depending on the successful candidate’s expertise and interest (e.g., in vivo models of metastatic breast cancer, protein chemistry and/or molecular biology).

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Dr Jodi Saunus directly for media enquiries about:

  • brain metastases
  • breast cancer
  • metastatic breast cancer
  • stage IV breast cancer

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au